EGM
VTGN icon

Engineers Gate Manager’s VistaGen Therapeutics VTGN Stock Holding History

Engineers Gate Manager’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,490
Closed -$20.2K – 2600
2025
Q4 		$20.2K Buy
+30,490
New +$110K ﹤0.01% 2027

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Engineers Gate Manager's VTGN Position: Q1 2026 in Review

Engineers Gate Manager sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 30,490 shares — an estimated $20.2K sold.

Engineers Gate Manager first reported a position in VTGN in Q4 2025 and held it in 1 quarter. The position peaked at $20.2K in Q4 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Engineers Gate Manager reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 30,490 VistaGen Therapeutics shares in Q1 2026, an estimated $20.2K.
  • Engineers Gate Manager first reported a position in VistaGen Therapeutics in Q4 2025 and held it in 1 quarter.
  • Engineers Gate Manager's VistaGen Therapeutics position peaked at $20.2K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Engineers Gate Manager's 13F filing for Q1 2026, filed 15 May 2026.